3 Horrendous Healthcare Stocks This Week   2-14-14
Upcoming SlideShare
Loading in...5

3 Horrendous Healthcare Stocks This Week 2-14-14



This week's worst-performing healthcare stocks

This week's worst-performing healthcare stocks



Total Views
Views on SlideShare
Embed Views



9 Embeds 8,993

http://www.fool.com 8748
http://m.fool.com 90
http://www.dailyfinance.com 87
http://www.barchart.com 43
http://translate.googleusercontent.com 18
http://cms.fool.com 3 2
http://www.greenwichtime.com 1
http://www.barchartenergy.com 1



Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
Post Comment
Edit your comment
  • http://www.fool.com/investing/general/2014/02/06/why-medidata-solutions-inc-shares-dipped.aspx
  • http://www.fool.com/investing/general/2014/02/06/why-affymetrix-inc-shares-dropped.aspx
  • http://www.fool.com/investing/general/2014/02/06/why-medidata-solutions-inc-shares-dipped.aspx
  • http://www.fool.com/investing/general/2014/02/06/why-medidata-solutions-inc-shares-dipped.aspx

3 Horrendous Healthcare Stocks This Week   2-14-14 3 Horrendous Healthcare Stocks This Week 2-14-14 Presentation Transcript

  • 3 Horrendous Health-Care Stocks This Week
  • Much of the U.S. was snowed under this week. Several health-care stocks unfortunately had the same experience -- with shivering plunges in share prices. Source: Wikimedia Commons.
  • Prana Biotechnology (Nasdaq: PRAN) The stock of the biotech focusing on neurological disorders dropped nearly 27% for the week.
  • Why Prana was pummeled • Summer Street analyst Bart Classen cast doubt on prospects for PBT2 in treating Alzheimer’s disease. • Classen thinks Prana’s phase 2b results for PBT2 don’t show statistically significant improvement. • PBT2 is also in phase 2a clinical trials targeting treatment of Huntington’s disease.
  • Galena BioPharma (Nasdaq: GALE) Shares of this biotech careened more than 24% this week.
  • Why Galena shares tanked • TheStreet’s Adam Feuerstein published a damaging article on Wednesday. • The article reported that Galena was linked to a stock-promotions firm that allegedly uses questionable tactics at the same time that insiders were selling. • Galena responded to the article – but only after a huge drop in its stock price.
  • The Medicines Company (Nasdaq: MDCO) The drugmaker’s shares fell nearly 14% this week.
  • Why The Medicines Company shares sank • An FDA advisory committee recommended against approval for antiplatelet agent cangrelor. • Concerns were voiced about the design of cangrelor’s clinical study. • The FDA isn’t bound by the recommendation – and makes its decision for approval by April 30.
  • Best shot at bouncing back? • Galena should have a reasonable chance at rebounding. • Insider selling after rising nearly 250% between Nov. 1 and Jan. 16 isn’t surprising. • Galena’s pipeline holds potential for the future.
  • Find out which stock The Motley Fool’s chief investment officer selected as the top pick for 2014 in our free report!